Gnrh (DrugBank: GnRH)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 76 | Pituitary gonadotropin secretion hyperthyroidism | 6 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000038202 | 2020-09-01 | 2020-09-13 | AMH combined INHB for the diagnosis of female central precocious puberty | AMH combined INHB for the diagnosis of female central precocious puberty | Central precocious puberty | Gold Standard:GnRHa provoctive test;Index test:Anti Mullerian hormone, Inhibin B; | Capital Institute of Pediatrics | NULL | Recruiting | 5 | 8 | Female | Target condition:150;Difficult condition:150 | China | |
| 2 | ChiCTR1800017120 | 2018-08-01 | 2018-07-12 | A real world study for the efficacy and safety of the combination therapy of GnRHa and recombinant human growth hormone in the treatment of central precocious puberty or rapid progressive adolescent girls | A real world study for the efficacy and safety of the combination therapy of GnRHa and recombinant human growth hormone in the treatment of central precocious puberty or rapid progressive adolescent girls. | precocious puberty | Case series:rhGH therapy; | The Children's Hospital, Zhejiang University School of Medicine | NULL | Recruiting | 3 | 12 | Female | Case series:700; | China | |
| 3 | ChiCTR1800016768 | 2018-06-25 | 2018-06-22 | A real world study on the efficacy and safety of the combination therapy of GnRHa and recombinant human growth hormone in the treatment of central precocious puberty or rapid progressive adolescent girls | A real world study on the efficacy and safety of the combination therapy of GnRHa and rhGH in the treatment of central precocious puberty or rapid progressive adolescent girls | Central precocious puberty or rapid progressive adolescence | Case series:GnRHa combined with rhGH; | The Children's Hospital, Zhe Jiang University School of Medcine | NULL | Recruiting | 6 | 12 | Female | Case series:700; | China | |
| 4 | NCT02993926 (ClinicalTrials.gov) | June 24, 2017 | 13/12/2016 | A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants | An Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious Puberty | Puberty, Central Precocious | Drug: Enantone;Drug: GnRH agonist | Takeda | NULL | Completed | N/A | N/A | All | 108 | China | |
| 5 | NCT00667446 (ClinicalTrials.gov) | December 2008 | 24/4/2008 | Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty | A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children With Central Precocious Puberty | Precocious;Leuprolide Acetate;Luteinizing Hormone (LH);Gonadotrophin-releasing Hormone Agonist (GnRHa);Tanner Staging;Depot Formulation;Suppression of LH;Central Precocious Puberty (CPP);Gonadotrophin-releasing Hormone (GnRH);Lupron;GnRH Analog;Pediatrics Central Precocious Puberty | Drug: Leuprolide Acetate 3 Month Depot | AbbVie (prior sponsor, Abbott) | NULL | Completed | N/A | N/A | All | 72 | Phase 3 | United States;Puerto Rico |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00438217 (ClinicalTrials.gov) | May 2006 | 21/2/2007 | Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children | Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children | Central Precocious Puberty | Drug: Triptorelin (GnRH agonists);Drug: Leuprolide (GnRH agonists) | University of Pisa | NULL | Recruiting | 1 Year | 18 Years | Both | 100 | Phase 4 | Italy |